Compositions and method for reducing TNFα levels

Details Compositions and method for reducing TNFα levels Compositions and method for reducing TNFα levels

2005-09-28

2010-10-26

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S200000

Reexamination Certificate

active

07820697

ABSTRACT:
1-Oxo- and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindolines substituted in the 4- and/or 7-position of the isoindoline ring and optionally further substituted in the 3-position of the 2,6-dioxopiperidine ring reduce the levels of inflammatory cytokines such as TNFα in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline.

REFERENCES:
patent: 4590189 (1986-05-01), Hiraga et al.
patent: 4808402 (1989-02-01), Leibovich et al.
patent: 4849441 (1989-07-01), Okazaki et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5712291 (1998-01-01), D'Amato
patent: 5798368 (1998-08-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6458810 (2002-10-01), Muller et al.
patent: 6476052 (2002-11-01), Muller et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 7041680 (2006-05-01), Muller et al.
patent: 7119106 (2006-10-01), Muller et al.
patent: 7323479 (2008-01-01), Zeldis
patent: WO 90/08128 (1990-07-01), None
patent: WO 92/18496 (1992-10-01), None
patent: WO 95/01348 (1995-01-01), None
Jonsson “Chemical structure . . . ” CA 78:43185 (1973).
Corral et al.,The Journal of Immunology, 380-386 (1999).
Corral et al.,Annals of Reumatic Diseases, 58(suppl. 1): 1107-1113 (1999).
Corral et al.,Molecular Medicine, 2(4): 506-515 (1996).
DeVita et al.,Cancer Principles and Practice, Lippincott, 144-145 (1985).
Gutman et al., CA 126:207258 (1997).
He et al., 206thAmerican Chemical Society National Meeting,Med. Chem. Abst. 216 (1993).
Jonsson,Acta. Pharm. Succica, 9: 431-436 (1972).
Jonsson,Acta. Pharm. Succica, 9: 521-542 (1972).
Joseph et al.,J. Nat'l. Canc. Inst., 90: 1648-1653 (1998).
Koch,Progress in Medicinal Chemistry, 22: 166-214 (1985).
Miyachi et al.,J. Med. Chem., 2858-2865 (1997).
Miyachi et al.,Chem. Pharm. Bull., 46(7): 1165-1168 (1998).
Miyachi et al.,Bioorg. Med. Chem. Letters, 6(19): 2293 (1996).
Moossa et al.,Comprehensive Textbook of Oncology, Williams & Silkins, 199-202 (1986).
Muller et al.,J. Med. Chem., 39(17): 3238-3240 (1996).
Muller et al.,Bioorg. Med. Chem. Letters, 9: 1625-1630 (1999).
Muller et al.,Bioorg. Med. Chem. Letters, 8: 2669-2674 (1998).
Nguyen et al., CA 126:324960 (1997).
Shannon et al.,Immunopharmacology, 35: 203-212 (1997).
Takeuchi et al.,Organic Letters, 1(10): 1571-1573 (1999).
Udagawa et al.,Angiogenic Agents in Cancer Therapy, Humana Press Inc., 263-274 (1998).

Affiliated with

Also associated with

Rating

Compositions and method for reducing TNFα levels does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and method for reducing TNFα levels, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and method for reducing TNFα levels will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4203932